2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Tarek H. Mouhieddine, discusses a study that evaluated outcomes in patients with relapsed/refractory multiple myeloma who progressed on bispecific antibodies.
Tarek H. Mouhieddine, MD, fellow, Hematology and Oncology, Icahn School of Medicine, Mount Sinai, discusses a study that evaluated outcomes in patients with relapsed/refractory multiple myeloma who progressed on bispecific antibodies.
During the 2021 ASH Annual Meeting and Exposition, findings from a study evaluating clinical outcomes and efficacy of salvage therapies in patients with relapsed/refractory multiple myeloma who progressed on bispecific antibodies were presented. Among 57 patients, the most common salvage therapy following progression on bispecific antibodies was another T-cell redirecting therapy, such as other bispecific antibodies or CAR T-cell therapies, Mouhieddine says. Some patients went on to respond to a second, third, or fourth T-cell redirecting therapy, suggesting that patients who progress on a T-cell redirecting therapy may respond to similar therapies, Mouhieddine explains. Moreover, of 18 patients who directly transitioned to a T-cell directed therapy, the median progression-free survival was 28.9 months, and the median overall survival was not met, Mouhieddine adds.
Overall, the main message from the study is that if patients relapse on 1 bispecific antibody, it does not mean that they won’t going to respond to another T-cell redirecting therapy, Mouhieddine continues. Patients who progress or relapse on a T-cell redirecting therapy should be given the chance with another one, as it seems they can still derive a response that can be maintained for 2 years, Mouhieddine concludes.